Can We Hang Our Hats on One Percent?

por LeVasseur, Nathalie, Gelmon, Karen A.
Publicado 2018

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective

por Ferrario, Cristiano, Christofides, Anna, Joy, Anil Abraham, Laing, Kara, Gelmon, Karen, Brezden-Masley, Christine
Publicado 2022

Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a “low-grade serous tubal intra-epithelial carcinoma” (STIC) on risk reducing surgery

por Chay, Wen Yee, Horlings, Hugo M., Tinker, Anna V., Gelmon, Karen A., Gilks, C.Blake
Publicado 2015

Effect of Eplerenone on Diastolic Function in Women Receiving Anthracycline-Based Chemotherapy for Breast Cancer

por Davis, Margot K., Villa, Diego, Tsang, Teresa S.M., Starovoytov, Andrew, Gelmon, Karen, Virani, Sean A.
Publicado 2019

Does age affect outcome with breast cancer?

por B Jackson, Emily, Gondara, Lovedeep, Speers, Caroline, Diocee, Rekha, M Nichol, Alan, Lohrisch, Caroline, A Gelmon, Karen
Publicado 2023

Gatekeeping in cancer clinical trials in Canada: The ethics of recruiting the “ideal” patient

por Bell, Jennifer A. H., Kelly, Mary T., Gelmon, Karen, Chi, Kim, Ho, Anita, Rodney, Patricia, Balneaves, Lynda G.
Publicado 2020

The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities

por Teckle, Paulos, Peacock, Stuart, McTaggart-Cowan, Helen, van der Hoek, Kim, Chia, Stephen, Melosky, Barb, Gelmon, Karen
Publicado 2011

Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D

por Teckle, Paulos, McTaggart-Cowan, Helen, Van der Hoek, Kim, Chia, Stephen, Melosky, Barb, Gelmon, Karen, Peacock, Stuart
Publicado 2013

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Canc...

por Rayson, Daniel, Gandhi, Sonal, Joy, Anil A., Brezden-Masley, Christine, Gelmon, Karen A., Sehdev, Sandeep, Cescon, David, Chia, Stephen
Publicado 2023

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

por Henning, Jan-Willem, Brezden-Masley, Christine, Gelmon, Karen, Chia, Stephen, Shapera, Shane, McInnis, Micheal, Rayson, Daniel, Asselah, Jamil
Publicado 2023

Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue...

por Crabb, Simon J, Bajdik, Chris D, Leung, Samuel, Speers, Caroline H, Kennecke, Hagen, Huntsman, David G, Gelmon, Karen A
Publicado 2008

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain

por Rayson, Daniel, Gandhi, Sonal, Joy, Anil A., Brezden-Masley, Christine, Gelmon, Karen A., Sehdev, Sandeep, Cescon, David, Chia, Stephen
Publicado 2022

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

por Jerzak, Katarzyna J., Bouganim, Nathaniel, Brezden-Masley, Christine, Edwards, Scott, Gelmon, Karen, Henning, Jan-Willem, Hilton, John F., Sehdev, Sandeep
Publicado 2023

Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer

por Landman, Yosef, Stemmer, Salomon Marcello, Sulkes, Aaron, Neiman, Victoria, Granot, Tal, Hendler, Daniel, Kramer, Mordechai Reuven, Gelmon, Karen, Yerushalmi, Rinat
Publicado 2019

Understanding breast cancer patients' preference for two types of exercise training during chemotherapy in an unblinded randomized controlled trial

por Courneya, Kerry S, Reid, Robert D, Friedenreich, Christine M, Gelmon, Karen, Proulx, Caroline, Vallance, Jeffrey K, McKenzie, Donald C, Segal, Roanne J
Publicado 2008

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases

por Rajput, Ashish B., Turbin, Dmitry A., Cheang, Maggie CU, Voduc, David K., Leung, Sam, Gelmon, Karen A., Gilks, C. Blake, Huntsman, David G.
Publicado 2007

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

por Habibi, Golareh, Leung, Samuel, Law, Jennifer H, Gelmon, Karen, Masoudi, Hamid, Turbin, Dmitry, Pollak, Michael, Nielsen, Torsten O, Huntsman, David, Dunn, Sandra E
Publicado 2008

QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reduction...

por Kalra, Jessica, Warburton, Corinna, Fang, Karen, Edwards, Lincoln, Daynard, Tim, Waterhouse, Dawn, Dragowska, Wieslawa, Sutherland, Brent W, Dedhar, Shoukat, Gelmon, Karen, Bally, Marcel
Publicado 2009

Patterns and predictors of exercise behavior during 24 months of follow-up after a supervised exercise program during breast cancer chemotherapy

por An, Ki-Yong, Kang, Dong-Woo, Morielli, Andria R., Friedenreich, Christine M., Reid, Robert D., McKenzie, Donald C., Gelmon, Karen, Mackey, John R., Courneya, Kerry S.
Publicado 2020

Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions:...

por Gelmon, Karen, Walshe, Janice M., Mahtani, Reshma, Joy, Anil A., Karuturi, Meghan, Neven, Patrick, Lu, Dongrui Ray, Kim, Sindy, Schnell, Patrick, Bananis, Eustratios, Schwartzberg, Lee
Publicado 2021